Primary Central Nervous System Lymphoma

Oncology·MeSH: Recurrence

Prevalence

56.0 / 100K

Incidence

19.6 / 100K/yr

14 drugs in development·6 companies·6 clinical trials

Drug Pipeline by Phase

Phase 3(5)

Drug	Company
Ibrutinib	Merck & Co., Inc. (MRK)
PD -1/PD-L1 monoclonal antibody	ENANTA PHARMACEUTICALS INC (ENTA)
tirabrutinib	Eton Pharmaceuticals, Inc. (ETON)
tirabrutinib	West Pharmaceutical Services Inc. (WST)
tirabrutinib	Deciphera Pharmaceuticals, Inc. (DCPH)

Phase 2(1)

Drug	Company
Orelabrutinib	ENANTA PHARMACEUTICALS INC (ENTA)

Phase 1(8)

Drug	Company
Cytarabine	Black Diamond Therapeutics, Inc. (BDTX)
Ibrutinib	Black Diamond Therapeutics, Inc. (BDTX)
Isavuconazole	Black Diamond Therapeutics, Inc. (BDTX)
Isavuconazole	ENANTA PHARMACEUTICALS INC (ENTA)
TEDD	ENANTA PHARMACEUTICALS INC (ENTA)
TEDD	Black Diamond Therapeutics, Inc. (BDTX)
TEDDI	Black Diamond Therapeutics, Inc. (BDTX)
TEDDI	ENANTA PHARMACEUTICALS INC (ENTA)

BioSniper tracks 14 drugs in development for Primary Central Nervous System Lymphoma across 6 companies.

There are 6 clinical trials targeting Primary Central Nervous System Lymphoma tracked by BioSniper.

The estimated prevalence of Primary Central Nervous System Lymphoma is approximately 56.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.